309 related articles for article (PubMed ID: 24158513)
21. Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice.
Shu L; Shayman JA
J Biol Chem; 2007 Jul; 282(29):20960-7. PubMed ID: 17535804
[TBL] [Abstract][Full Text] [Related]
22. Role of protein kinase A and class II phosphatidylinositol 3-kinase C2β in the downregulation of KCa3.1 channel synthesis and membrane surface expression by lyso-globotriaosylceramide.
Choi JY; Park S
Biochem Biophys Res Commun; 2016 Feb; 470(4):907-12. PubMed ID: 26820527
[TBL] [Abstract][Full Text] [Related]
23. Visualization of Rab5 activity in living cells by FRET microscopy and influence of plasma-membrane-targeted Rab5 on clathrin-dependent endocytosis.
Galperin E; Sorkin A
J Cell Sci; 2003 Dec; 116(Pt 23):4799-810. PubMed ID: 14600265
[TBL] [Abstract][Full Text] [Related]
24. Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice.
Rodrigues LG; Ferraz MJ; Rodrigues D; Pais-Vieira M; Lima D; Brady RO; Sousa MM; Sá-Miranda MC
Neurobiol Dis; 2009 Jan; 33(1):48-56. PubMed ID: 18848893
[TBL] [Abstract][Full Text] [Related]
25. Absence of α-galactosidase cross-correction in Fabry heterozygote cultured skin fibroblasts.
Fuller M; Mellett N; Hein LK; Brooks DA; Meikle PJ
Mol Genet Metab; 2015 Feb; 114(2):268-73. PubMed ID: 25468650
[TBL] [Abstract][Full Text] [Related]
26. Prominent role of KCa3.1 in endothelium-derived hyperpolarizing factor-type dilations and conducted responses in the microcirculation in vivo.
Wölfle SE; Schmidt VJ; Hoyer J; Köhler R; de Wit C
Cardiovasc Res; 2009 Jun; 82(3):476-83. PubMed ID: 19218287
[TBL] [Abstract][Full Text] [Related]
27. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
[TBL] [Abstract][Full Text] [Related]
28. Expression of genes and their responses to enzyme replacement therapy in a Fabry disease mouse model.
Park ES; Choi JO; Park JW; Lee MH; Park HY; Jung SC
Int J Mol Med; 2009 Sep; 24(3):401-7. PubMed ID: 19639234
[TBL] [Abstract][Full Text] [Related]
29. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
[TBL] [Abstract][Full Text] [Related]
30. iNOS-Derived Nitric Oxide Induces Integrin-Linked Kinase Endocytic Lysosome-Mediated Degradation in the Vascular Endothelium.
Reventun P; Alique M; Cuadrado I; Márquez S; Toro R; Zaragoza C; Saura M
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1272-1281. PubMed ID: 28546219
[TBL] [Abstract][Full Text] [Related]
31. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer.
Takahashi H; Hirai Y; Migita M; Seino Y; Fukuda Y; Sakuraba H; Kase R; Kobayashi T; Hashimoto Y; Shimada T
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13777-82. PubMed ID: 12370426
[TBL] [Abstract][Full Text] [Related]
32. ESCRT-dependent targeting of plasma membrane localized KCa3.1 to the lysosomes.
Balut CM; Gao Y; Murray SA; Thibodeau PH; Devor DC
Am J Physiol Cell Physiol; 2010 Nov; 299(5):C1015-27. PubMed ID: 20720181
[TBL] [Abstract][Full Text] [Related]
33. Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease.
Namdar M; Gebhard C; Studiger R; Shi Y; Mocharla P; Schmied C; Brugada P; Lüscher TF; Camici GG
PLoS One; 2012; 7(4):e36373. PubMed ID: 22558451
[TBL] [Abstract][Full Text] [Related]
34. Role of ubiquitylation and USP8-dependent deubiquitylation in the endocytosis and lysosomal targeting of plasma membrane KCa3.1.
Balut CM; Loch CM; Devor DC
FASEB J; 2011 Nov; 25(11):3938-48. PubMed ID: 21828287
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of alpha-galactosidase A upregulates CD77: functional impact for Fabry nephropathy.
Thomaidis T; Relle M; Golbas M; Brochhausen C; Galle PR; Beck M; Schwarting A
Kidney Int; 2009 Feb; 75(4):399-407. PubMed ID: 19037253
[TBL] [Abstract][Full Text] [Related]
36. Altered dynamics of a lipid raft associated protein in a kidney model of Fabry disease.
Labilloy A; Youker RT; Bruns JR; Kukic I; Kiselyov K; Halfter W; Finegold D; do Monte SJ; Weisz OA
Mol Genet Metab; 2014 Feb; 111(2):184-92. PubMed ID: 24215843
[TBL] [Abstract][Full Text] [Related]
37. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease.
Auray-Blais C; Cyr D; Ntwari A; West ML; Cox-Brinkman J; Bichet DG; Germain DP; Laframboise R; Melançon SB; Stockley T; Clarke JT; Drouin R
Mol Genet Metab; 2008 Mar; 93(3):331-40. PubMed ID: 18023222
[TBL] [Abstract][Full Text] [Related]
38. Vascular endothelial growth factor (VEGF-a) in Fabry disease: association with cutaneous and systemic manifestations with vascular involvement.
Zampetti A; Gnarra M; Borsini W; Giurdanella F; Antuzzi D; Piras A; Smaldone C; Pieroni M; Cadeddu C; de Waure C; Feliciani C
Cytokine; 2013 Mar; 61(3):933-9. PubMed ID: 23332617
[TBL] [Abstract][Full Text] [Related]
39. KCa 3.1 upregulation preserves endothelium-dependent vasorelaxation during aging and oxidative stress.
Choi S; Kim JA; Li HY; Shin KO; Oh GT; Lee YM; Oh S; Pewzner-Jung Y; Futerman AH; Suh SH
Aging Cell; 2016 Oct; 15(5):801-10. PubMed ID: 27363720
[TBL] [Abstract][Full Text] [Related]
40. Dysregulation of Immune Response Mediators and Pain-Related Ion Channels Is Associated with Pain-like Behavior in the GLA KO Mouse Model of Fabry Disease.
Spitzel M; Wagner E; Breyer M; Henniger D; Bayin M; Hofmann L; Mauceri D; Sommer C; Üçeyler N
Cells; 2022 May; 11(11):. PubMed ID: 35681422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
